Research Domain Criteria Database (RDoCdb) Data Sharing Plan

9/15/2014

i. Data Sharing Overview

All de-identified data resulting from this NIH-funded award are expected to be submitted to the Research Domain Criteria database (RDoCdb), along with appropriate supporting documentation to enable efficient and appropriate use of the data. The goal of this data sharing policy is to enable rapid, widespread sharing of high-quality, human-subjects data to the research community, and thereby maximize the value and utility of the data and the research.

NIMH has established a two-tiered approach for data submission to, and sharing through, the RDoCdb. The first tier is for the submission of descriptive/raw data while the study is ongoing (see Definitions). First-tier data will be made available to qualified researchers in a timely manner, via the RDoCdb access procedures, as described in Section vi. below. The second tier is for the submission of analyzed data at the publication of results or when the study’s primary aims have been achieved (to be determined in consultation with the NIMH Program Official overseeing the award; see Definitions). This tiered approach enables data sharing with the research community as soon as possible, without compromising the ability of Principal Investigators to interpret and communicate their findings formally.

ii. Submission Schedule for Descriptive/Raw Data

Descriptive/raw data are data used to characterize a research subject (see Definitions), including data from standard diagnostic assessments, standard clinical measures, family/subject medical history, demographic data, raw unprocessed images, -omics (e.g. proteomics, genomics, metabolomics) data, raw neurosignaling recordings, and genetic test results that are being collected in the course of the clinical trial. Analyzed data, outcome variables, processed neurosignal recordings, etc., are not considered descriptive/raw data.

Descriptive/raw data are expected to be submitted to the RDoCdb on a semi-annual basis (on or before January 15 and July 15, beginning six months after the award budget period has begun). RDoCdb support staff will contact the Principal Investigator following award to plan an appropriate data submission schedule. NIH expects cumulative submission of descriptive/raw data during each submission cycle, which will enable data corrections throughout the duration of the award. Raw -omic, EEG, and neuroimaging data are expected to be submitted incrementally as new data are acquired.
iii. Submission Schedule for Analyzed Data

Analyzed data (see Definitions) are expected to be submitted at the time of publication. Even if a publication focuses on only part of an analyzed dataset, the entire analyzed dataset should be submitted when the first paper is published. The data that are not part of the paper will not be shared immediately with the research community, but rather along the timeline described in the Data Sharing section below.

Analyzed data include:

- Results.
- Data from custom or proprietary clinical assessments/measures that support the aims of the proposed research or are otherwise not included in the semi-annual submissions.
- Final data and/or images derived from processed images (see Definitions).
- Sufficient supporting documentation to enable efficient and appropriate use of the data by the broader research community (see Definitions).
- All other de-identified research data acquired through the supported award but not explicitly listed here.

Additionally, Principal Investigators are expected to associate the data deposited in the RDoCdb with their publications/findings—both positive and negative—using the RDoCdb Study feature (see http://rdocdb.nimh.nih.gov/results/).

Provisions for Data Submission into RDoCdb

- All human-subjects data provided must include a Global Unique Identifier (GUID) and must not include personally identifiable information (PII).
- Submission of data into and sharing of data via RDoCdb should be mentioned in the informed consent process of the study.
- The awarded institution and Principal Investigator must ensure that submission and sharing via RDoCdb are consistent with the informed consent of study participants from whom the data are obtained.
- All data collected on all human subjects involved in this NIH-supported award are expected to be provided, including data from control subjects. The total number of subjects for which data are provided should be consistent with the total number of subjects reported in the annual progress report.
- In the event that the research involves custom or proprietary measures not currently defined in the RDoCdb Data Dictionary, the principal investigator will ensure the definition of the data by defining the specific data elements and sending these definitions to RDoCdb for curation. Once these measures have been defined, the associated data can then be submitted to RDoCdb.
- NIH expects individual subject-level data, rather than summary/aggregate data.
- Due to the challenges inherent in de-identifying video footage, video material should not be submitted.
- The Principal Investigator is expected to communicate this data sharing plan to appropriate research staff to ensure the timely submission of data.
iv. Data Sharing Schedule

All submitted data (both descriptive/raw and analyzed data) will be made available for access by qualified members of the research community according to the provisions defined in the NIMH Data Repositories Data Access Agreement and Use Certification. These procedures are intended to allow investigators sufficient time for data verification, and for submission of primary publications based on the collected data.

Descriptive/raw research data are made available for access to other researchers within **four (4) months after submission**, allowing the Principal Investigator and his/her team sufficient time to complete appropriate quality assurance/quality control (QA/QC) procedures. Thus, there would be between five (5) and eleven (11) months from collection to sharing of descriptive/raw data. Descriptive/raw data from biospecimens are expected to be shared when the sample is banked.

Analyzed research data are expected to be submitted to the RDoCdb at the time a publication is accepted and shared when the publication is released. Unpublished data are expected to be submitted prior to project completion and will be shared within one year after the original project completion date, or when the data are published, whichever comes first.

In the event circumstances arise during the course of the award which the Principal Investigator believes necessitate deviations from this schedule, the Principal Investigator must receive approval from the NIMH Program Official overseeing the award.

v. Privacy

All data (see Definitions) made available for public use via RDoCdb will be de-identified data, such that the identities of participants cannot be readily ascertained or otherwise associated with the data by the RDoCdb staff or secondary data users. Submissions of data to RDoCdb must be accompanied by the RDoCdb Data Submission Agreement, which is expected within 3 months of award.

vi. Data Access for Research Purposes

Access to data for research purposes will be provided through the RDoCdb Data Access Committee (DAC). Investigators and institutions seeking data from RDoCdb will be expected to meet data security measures and will be asked to submit a data access request, including a Data Use Certification, which is co-signed by the investigator and the designated Institutional Official(s) at the NIH-recognized sponsoring institution with a current Federal Wide Assurance (FWA).
vii. Definitions

**Analyzed Data:** Data specific to the primary aims of the research being conducted (e.g., outcome measures, other dependent variables, observations, laboratory results, analyzed images, volumetric data, etc.).

**Cumulative data:** A dataset that includes all data collected from the beginning of the study to designated time point; each submission replaces previously submitted datasets in order to avoid the challenges of tracking interim changes or corrections in the database. Data containing references to large files (e.g., genomic, imaging, and other rich data types), may be provided incrementally for efficiency reasons.

**Data:** For human subjects, data include all research and clinical assessments and information obtained via interviews, direct observations, laboratory tasks and procedures, records reviews, genetic and genomic data, neuroimaging data, psychophysiological assessments, data from physical examinations, etc. The following are not included as data: laboratory notebooks, preliminary analyses, drafts of scientific papers, plans for future research, peer review reports, communications with colleagues, or physical objects, such as gels or laboratory specimens.

**Descriptive/raw data:** Descriptive/raw data include family/medical history, demographic data, data from standard diagnostic instruments, or custom measures supporting a categorization of a subject’s phenotype. Additionally, raw unprocessed images and -omic data files are also categorized as descriptive/raw data. For longitudinal neuroimaging studies, where images at different time points are considered outcome measures, only baseline raw images are expected as descriptive/raw data.

**Experiment definition:** The Principal Investigator is expected to use the RDoCdb Experimental Definition Tool, an online resource, to provide enough information to allow other researchers to repeat the experiment (http://ndct.nimh.nih.gov/submit/#tab-3). For -omics data, experiment definition information includes the experimental molecule, the technology and experimental platform, protocols used for molecule and experiment preparation and kits used for these purposes, as well as names of analysis software, experimental equipment, and description of analysis protocols. For neurosignal recordings, experiment definition includes timing sequences, event definition, and acquisition hardware/software specification.

**Neurosignal Recordings:** EEG, MEG, Eye Tracking, and fMRI experiments are supported using the experiment definition tool. For these event based experiments, usually involving specific acquisition definitions and timing sequences, standardized metadata is needed. RDoCdb provides a simple interface to specify the metadata supporting these types of experiments.

**-Omic data:** Descriptive/raw genomic data are defined as the raw or primary data specific to the technology platform used for the research study. If a microarray technology is used, an
example of descriptive/raw data is the intensity data such as an Affymetrix CEL file. Descriptive/raw data submissions from research studies using the next generation of sequencing technology should include the read data, the second most frequent base and the quality data. Formats for these submissions include fastq, AB SOLiD Native, AB SOLiD SRF, Illumina Native, Illumina SRF, and Roche 454 SFF.

Analyzed genomic data are defined as data derived from the primary or raw data. For the example of the next generation of sequencing technology, analyzed data would be alignments or mapped data in the BAM (Binary Alignment/Map) format or the Sequence Alignment/Map (SAM) Format. Examples of analyzed data from the SNP microarray technology would include copy number and/or genotype. For the gene expression microarray technology, an example of analyzed data would be normalized gene expression levels.

**Processed images:** Derived data generated as the final result of image analysis applications in any standard medical research format (e.g. NIFTI, AFNI, etc.). If applicable, supporting de-identified video and imaging materials that define the experiment (e.g., timing sequences in fMRI) should accompany processed images. Intermediate image datasets should not be submitted unless the investigator feels that they are pertinent.

**Raw unprocessed images:** Data acquired from a scanner in a standard medical imaging format. DICOM format is expected.

**Supporting documentation:** Clear documentation expected in order to enable an investigator unfamiliar with the dataset to understand and use the data. For example, supporting documentation may include non-copyrighted data collection forms, study procedures and protocols, data dictionary rationale, exclusion criteria, website references, a listing of major study publications, and the definition of a genomic experiment using the RDoCdb Experiment Definition Tool. Definition related to a specific finding or publication is to be defined and documented through the RDoCdb Study feature.